Clinical Trial Update: MORDOR II Burkina Faso: Longitudinal Trial [Phase 4]

View source ↗

Summary

Phase 4 longitudinal trial update (MORDOR II Burkina Faso) completed; results posted in 2023 regarding child growth, microbiome diversity, child mortality, and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Antibiotic Resistance
• Child Growth Disorders
• Child Mortality
• Diversity of Microbiome Disorders

Snippet

Sponsor: University of California, San Francisco | Conditions: Child Growth, Diversity of Microbiome | Phase 4 | Status: COMPLETED | Results posted: 2023-08-09